1 citations
,
December 2024 in “Dermatology and Therapy” The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.
1 citations
,
June 2024 in “Cosmoderma” Most patients with alopecia areata in Syria are young adult males, often with patchy scalp hair loss.
1 citations
,
July 2023 in “Al-Azhar Medical Journal” Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
1 citations
,
January 2023 Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.
1 citations
,
January 2022 in “Medical Science” People with Alopecia Areata have a higher risk of heart-related health issues.
1 citations
,
October 2021 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for severe alopecia areata show promise but lack standard approval.
1 citations
,
November 2017 in “Journal of Investigative Dermatology” Platelet-rich plasma and microneedling could potentially help hair regrowth in alopecia areata patients, but more research is needed.
1 citations
,
February 2015 in “Journal of evolution of medical and dental sciences” 0.05% Betamethasone Dipropionate is the most effective topical treatment for alopecia areata.
1 citations
,
January 2014 in “Hair therapy & transplantation” Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
June 2026 in “International Journal of Dermatology Venereology and Leprosy Sciences” Alopecia areata patients may have higher blood pressure and blood sugar, indicating a future risk of metabolic issues.
May 2026 in “Jurnal Sehat Indonesia (JUSINDO)” Low vitamin D levels may worsen or cause alopecia areata.
April 2026 in “Boletín Médico Del Hospital Infantil de México (English Edition)” Most kids with alopecia areata have other health issues, often allergies or skin conditions.
STS01 1% effectively promotes hair regrowth with minimal side effects.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata cases in children are rising, especially in females and low-income regions, with a projected increase in China and decrease in the USA.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
December 2025 in “Reports of Morphology” Men with alopecia areata have different body fat distribution compared to healthy men.
November 2025 in “The Journal of Medical Sciences” Intralesional triamcinolone is more effective than cryotherapy for treating alopecia areata in middle-aged adults.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
October 2025 in “Journal of Skin and Sexually Transmitted Diseases” Alopecia areata patients often have undetected thyroid issues, so routine thyroid screening is recommended.
September 2025 in “Meditsinskiy sovet = Medical Council” Atopic dermatitis significantly increases the risk of alopecia areata, especially in children.
September 2025 in “Journal of Skin and Stem Cell” The combination of calcipotriol and PRP is the most effective treatment for alopecia areata.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
August 2025 in “Frontiers in Immunology” People with alopecia areata have a higher risk of heart disease.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.